{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:30:49Z","timestamp":1793223049102,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015722","name":"Centre Hospitalier Universitaire de Clermont-Ferrand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.bcp.2025.117663","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T15:32:16Z","timestamp":1766331136000},"page":"117663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Inflammatory protein signatures associated with high rivaroxaban exposure"],"prefix":"10.1016","volume":"245","author":[{"given":"Catherine","family":"Feliu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-418X","authenticated-orcid":false,"given":"Jean","family":"Escal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Leven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Hodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Rigaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gonzalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Coutureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Lacut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Thereaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7134-0713","authenticated-orcid":false,"given":"Xavier","family":"Delavenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bcp.2025.117663_b0005","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1016\/S2352-3026(24)00281-3","article-title":"Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants","volume":"11","author":"Ageno","year":"2024","journal-title":"Lancet Haematol."},{"issue":"11","key":"10.1016\/j.bcp.2025.117663_b0010","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/bcp.14071","article-title":"Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): a cross-national drug utilization study","volume":"85","author":"Ib\u00e1\u00f1ez","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"10264","key":"10.1016\/j.bcp.2025.117663_b0015","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2025.117663_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bcp.2025.117663_b0025","doi-asserted-by":"crossref","unstructured":"S. Cormier, D.M. Siegal, A framework for managing severe DOAC-related bleeding: Recognize, Reverse, Resume, Reduce, Thromb. Update 15. 2024 Feb; 100165. doi: 10.1016\/j.tru.2024.100165.","DOI":"10.1016\/j.tru.2024.100165"},{"issue":"6","key":"10.1016\/j.bcp.2025.117663_b0030","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2014-03-563577","article-title":"Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry","volume":"124","author":"Beyer-Westendorf","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bcp.2025.117663_b0035","first-page":"1036","article-title":"Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care","volume":"33","author":"Gulilat","year":"2017","journal-title":"Can. J. Cardiol."},{"issue":"8","key":"10.1016\/j.bcp.2025.117663_b0040","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00228-019-02693-2","article-title":"Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation","volume":"75","author":"Mikli\u010d","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"16","key":"10.1016\/j.bcp.2025.117663_b0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12959-018-0183-3","article-title":"Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study","volume":"12","author":"Sennesael","year":"2018","journal-title":"Thromb. J."},{"issue":"1","key":"10.1016\/j.bcp.2025.117663_b0050","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/jpet.111.180240","article-title":"In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban","volume":"338","author":"Gnoth","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.bcp.2025.117663_b0055","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1038\/s41598-018-28622-4","article-title":"Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines","volume":"8","author":"Sennesael","year":"2018","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.bcp.2025.117663_b0060","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00228-019-02639-8","article-title":"Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study","volume":"75","author":"Zdovc","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"57","key":"10.1016\/j.bcp.2025.117663_b0065","article-title":"ABCG2 polymorphism and rivaroxaban pharmacokinetics in healthy individuals after a single dose","volume":"1","author":"Santos","year":"2024","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"7 Suppl","key":"10.1016\/j.bcp.2025.117663_b0070","first-page":"S24","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can. J. Cardiol."},{"issue":"5","key":"10.1016\/j.bcp.2025.117663_b0075","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1365-2125.2010.03753.x","article-title":"Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct factor Xa inhibitor","volume":"70","author":"Kubitza","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"12","key":"10.1016\/j.bcp.2025.117663_b0080","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s40262-022-01160-z","article-title":"Rivaroxaban Pharmacokinetics in Obese Subjects: a Systematic Review","volume":"61","author":"Alalawneh","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"649","key":"10.1016\/j.bcp.2025.117663_b0085","article-title":"An extension of biorelevant fed-state dissolution tests to clinical pharmacokinetics - a study on gastrointestinal factors influencing rivaroxaban exposure and efficacy in atrial fibrillation patients","volume":"5","author":"Roma\u0144ski","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.bcp.2025.117663_b0090","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1016\/j.jtha.2024.06.024","article-title":"Full-dose rivaroxaban in patients with a history of bariatric surgery: bridging the knowledge gap through a phase 1 study","volume":"22","author":"Leven","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcp.2025.117663_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmpk.2020.09.006","article-title":"Quantitative and targeted proteomics-based identification and validation of drug efficacy biomarkers","volume":"36","author":"Masuda","year":"2021","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"7\u20138","key":"10.1016\/j.bcp.2025.117663_b0100","article-title":"Opportunities for pharmacoproteomics in biomarker discovery","volume":"23","author":"Poulos","year":"2023","journal-title":"Proteomics"},{"issue":"5","key":"10.1016\/j.bcp.2025.117663_b0105","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kead390","article-title":"Proteomics analyses of human plasma reveal triosephosphate isomerase as a potential blood marker of methotrexate resistance in rheumatoid arthritis","volume":"63","author":"Escal","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.bcp.2025.117663_b0110","first-page":"602","article-title":"Drug disease interactions: role of inflammatory mediators in disease and variability in drug response","volume":"8","author":"Kulmatycki","year":"2005","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2025.117663_b0115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1081\/DMR-120018247","article-title":"Cytokine regulation of P-glycoprotein","volume":"35","author":"McRae","year":"2003","journal-title":"Drug Metab. Rev."},{"issue":"12","key":"10.1016\/j.bcp.2025.117663_b0120","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1172\/JCI200318921","article-title":"C-reactive protein: a critical update","volume":"111","author":"Pepys","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.bcp.2025.117663_b0125","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1253\/circj.CJ-19-1006","article-title":"Persistent Systemic Inflammation is Associated with Bleeding Risk in Atrial Fibrillation patients","volume":"84","author":"Hamanaka","year":"2020","journal-title":"Circ J"},{"issue":"12","key":"10.1016\/j.bcp.2025.117663_b0130","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1111\/bcp.15495","article-title":"Effects of inflammation on voriconazole levels: a systematic review","volume":"88","author":"Li","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2025.117663_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107627","article-title":"Inflammation is a major regulator of drug metabolizing enzymes and transporters: Consequences for the personalization of drug treatment","volume":"215","author":"Stanke-Labesque","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2025.117663_b0140","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2022.04.004","article-title":"Lipoprotein(a): an underestimated inflammatory mastermind","volume":"349","author":"Dzobo","year":"2022","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.bcp.2025.117663_b0145","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.119.316206","article-title":"Atherogenic Lipoprotein(a) increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation","volume":"126","author":"Schnitzler","year":"2020","journal-title":"Circ. Res."},{"issue":"10","key":"10.1016\/j.bcp.2025.117663_b0150","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.cmet.2024.08.009","article-title":"PDIA3 defines a novel subset of adipose macrophages to exacerbate the development of obesity and metabolic disorders","volume":"36","author":"Luo","year":"2024","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.bcp.2025.117663_b0155","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.bbrc.2019.08.100","article-title":"PDIA3-regulted inflammation and oxidative stress contribute to the traumatic brain injury (TBI) in mice","volume":"518","author":"Wang","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.bcp.2025.117663_b0160","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/cts.13507","article-title":"Assessment of the drug-drug interaction potential for therapeutic proteins with pro-inflammatory activities","volume":"16","author":"Yu","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"5","key":"10.1016\/j.bcp.2025.117663_b0165","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.3390\/ijms24054900","article-title":"Direct Oral FXa Inhibitors Binding to Human Serum Albumin: Spectroscopic, Calorimetric, and Computational Studies","volume":"24","author":"Mari\u00f1o-Ocampo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117663_b0170","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s11239-020-02092-w","article-title":"Albumin and bleed risk in rivaroxaban treated patients","volume":"50","author":"Wojakowski","year":"2020","journal-title":"J. Thromb. Thrombolysis"},{"issue":"2","key":"10.1016\/j.bcp.2025.117663_b0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/jpen.1451","article-title":"Hypoalbuminemia: Pathogenesis and Clinical significance","volume":"43","author":"Soeters","year":"2019","journal-title":"JPEN J. Parenter. Enteral Nutr."},{"issue":"1","key":"10.1016\/j.bcp.2025.117663_b0180","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nrd2353","article-title":"Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery","volume":"7","author":"Wasan","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1\u20133","key":"10.1016\/j.bcp.2025.117663_b0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.theochem.2009.09.011","article-title":"Molecular structure, lipophilicity, solubility, absorption, and polar surface area of novel anticoagulant agents","volume":"916","author":"Remko","year":"2009","journal-title":"J. Mol. Struct. THEOCHEM"},{"issue":"548","key":"10.1016\/j.bcp.2025.117663_b0190","article-title":"ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disorders","volume":"1","author":"Singh","year":"2023","journal-title":"Clin. Chim. Acta"},{"issue":"10","key":"10.1016\/j.bcp.2025.117663_b0195","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jchf.2022.06.005","article-title":"Angiotensinogen: more than its Downstream Products: evidence from Population Studies and Novel Therapeutics","volume":"10","author":"Kahlon","year":"2022","journal-title":"JACC Heart Fail."},{"issue":"2","key":"10.1016\/j.bcp.2025.117663_b0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3390\/antiox13020215","article-title":"Regulation of P-Glycoprotein during Oxidative stress","volume":"13","author":"Shchulkin","year":"2024","journal-title":"Antioxidants (Basel)"},{"issue":"26","key":"10.1016\/j.bcp.2025.117663_b0205","doi-asserted-by":"crossref","first-page":"11137","DOI":"10.3389\/jpps.2023.11137","article-title":"Drug-disease interaction: Clinical consequences of inflammation on drugs action and disposition","volume":"6","author":"Abdallah","year":"2023","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.bcp.2025.117663_b0210","first-page":"359","article-title":"Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality","volume":"7","author":"Fernandez","year":"2004","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2025.117663_b0215","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.bcp.2025.117663_b0220","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13318-021-00744-7","article-title":"In Vitro Evaluation of P-gp-Mediated Drug-Drug Interactions using the RPTEC\/TERT1 Human Renal Cell Model","volume":"47","author":"Saib","year":"2022","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.bcp.2025.117663_b0225","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.3390\/pharmaceutics13101544","article-title":"Inflammation Induces changes in the Functional Expression of P-gp, BCRP, and MRP2: an Overview of Different Models and Consequences for Drug Disposition","volume":"13","author":"Saib","year":"2021","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bcp.2025.117663_b0230","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1055\/s-0040-1701206","article-title":"Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: a Post Hoc Analysis of the X-VeRT Trial","volume":"4","author":"Kirchhof","year":"2020","journal-title":"TH Open."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225009281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225009281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T12:17:01Z","timestamp":1781698621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225009281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":46,"alternative-id":["S0006295225009281"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117663","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inflammatory protein signatures associated with high rivaroxaban exposure","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117663"}}